50,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Diadema Partners LP

Diadema Partners LP purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company's stock, valued at approximately $532,000. Diadema Partners LP owned about 0.21% of UroGen Pharma as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in URGN. State Street Corp raised its stake in shares of UroGen Pharma by 5.9% during the third quarter. State Street Corp now owns 769,583 shares of the company's stock valued at $9,774,000 after acquiring an additional 42,907 shares during the last quarter. Barclays PLC increased its holdings in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after purchasing an additional 48,040 shares during the period. Geode Capital Management LLC grew its stake in UroGen Pharma by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock valued at $5,787,000 after purchasing an additional 34,248 shares during the last quarter. Tidal Investments LLC increased its stake in UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock worth $477,000 after buying an additional 6,030 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in UroGen Pharma by 263.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after acquiring an additional 49,318 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $9.66 on Tuesday. UroGen Pharma Ltd. has a 52-week low of $8.94 and a 52-week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market cap of $445.27 million, a price-to-earnings ratio of -3.07 and a beta of 0.80. The business's fifty day moving average is $10.48 and its 200 day moving average is $11.15.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. Research analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. Scotiabank initiated coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective on the stock. HC Wainwright decreased their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. Finally, The Goldman Sachs Group reduced their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, UroGen Pharma presently has a consensus rating of "Buy" and an average target price of $32.86.

Insider Activity

In other news, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UroGen Pharma Ltd. (NASDAQ:URGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.